Attendees of the 2024 Annual Leadership Meeting of The American Orthopaedic Association will discuss and debate, formally and informally, controversies in orthopaedic practice, science, ethics, education, economics, and social issues. Physicians will also advance their knowledge of orthopaedic surgery and science and learn new practices that can be implemented to improve patient care.
Program Objectives
Continuing Medical Education (CME)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the North American Spine Society and the American Orthopaedic Association. The North American Spine Society is accredited by the ACCME to provide continuing medical education for physicians.
AOA Annual Leadership Meeting: The North American Spine Society designates this live activity for a maximum of 13.0 AMA PRA Category 1 Credits™.
Summer CORD Conference: The North American Spine Society designates this live activity for a maximum of 5.5 AMA PRA Category 1 Credits™.
Own the Bone Symposium: The North American Spine Society designates this live activity for a maximum of 7.5 AMA PRA Category 1 Credits™.
The National Association of Orthopaedic Nurses (NAON) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission of Accreditation, and up to 7.5 hours of Category A nursing contact hours are available for this Own the Bone event.
Emerging Leaders Forum: The North American Spine Society designates this live activity for a maximum of 10.5 AMA PRA Category 1 Credits™.
Program Education, Accreditation, and Leadership (PEAL) Forum: The North American Spine Society designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™
DEI Forum: The North American Spine Society designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™
Disclosures/Disclaimers
Disclosure
Each Annual Meeting speaker has been asked to disclose if he or she, or a member of their immediate family, has a financial interest or other relationship with a commercial company or institution, which relates directly or indirectly to the subject of his or her presentation.
An indication of the participant’s disclosure will appear online after his or her name, as well as the commercial company or institution that provided the support. If the participant discloses he or she does not have any financial interests or commitments, this information will also be noted. The AOA does not view the existence of these disclosed interests or commitments as necessarily implying bias or decreasing the value of the author’s participation in the Annual Meeting. An indication of the participant’s disclosure will appear on the AOA’s website.
FDA Disclaimer
Some drugs or medical devices demonstrated at the Annual Meeting have not been cleared by the FDA or have been cleared by the FDA for specific purposes only. The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or medical device he or she wishes to use in clinical practice.
The AOA’s policy provides that “off label” uses of a device or pharmaceutical may be described in the AOA’s CME activities so long as the “off label” status of the device or pharmaceutical is also specifically disclosed (i.e. it must be disclosed that the FDA has not approved labeling the device for the described purpose). Any device or pharmaceutical is being used “off label” if the described use is not set forth on the product’s approval label.